Methamphetamine Use Disorder – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Methamphetamine use disorder refers to the illicit use of methamphetamines as a drug of abuse. It is a cationic lipophilic molecule that stimulates the release, and partially blocks the reuptake, of newly synthesized catecholamines in the CNS (Cho and Melega, 2002). Due to its structural similarity, methamphetamine substitutes for the dopamine transporter (DAT), noradrenaline transporter (NET), serotonin transporter (SERT), and vesicular monoamine transporter-2 (VMAT-2) and reverses their endogenous function, thereby redistributing monoamines from storage vesicles into the cytosol. Further, the majority of individuals admitted to treatment were non-Hispanic White (69%), followed by individuals of Mexican origin.

 

Methamphetamine dependence is largely a disorder of the White population; however, this may be a byproduct of the regional variability in methamphetamine use, which is currently greatest in the West and parts of the Midwest.

The rates of methamphetamine dependence appear to be roughly equivalent in men compared to women, with 53% of primary methamphetamine/amphetamine admissions being male.

 

The competitive landscape of Methamphetamine Use Disorder includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Methamphetamine Use Disorder across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Methamphetamine Use Disorder Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Methamphetamine Use Disorder – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          IXT-m200         InterveXion Therapeutics, LLC   Phase 2

2          Acamprosate    Forest Laboratories       Phase 1/2

3          Naltrexone: Vivitrol®      The Emmes Company, LLC       Phase 3

4          Naltrexone        Alkermes, Inc.   Phase 2

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033